<b>→</b>	+	

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PT
------------------------------

Signature

## STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	1

Compl	Complete if Known				
Application Number	10/605,703				
Filing Date	10/21/2003				
First Named Inventor	Foo, Thomas K.F.				
Group Art Unit	Unknown				
Examiner Name	Unknown				
Attorney Docket Number	GEMS8081.179				

OTHER PRIO	R ART -	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
Lua.		ELKINGTON, A. et al., Interstudy Reproducibility of Myocardial Perfusion Reserve Using a Novel Dual Acquisition Cardiovascular Magnetic Resonance Sequence, Poster Abstracts: Clinical MRI – Ischemic Heart Disease, Society for Cardiovascular Magnetic Resonance, 2003, #244, p. 107.	·
LMA.		SLAVIN, G. et al., First-Pass Myocardial Perfusion MRI With Interleaved Notched Saturation: Feasibility Study, Radiology 2001, vol. 219, pp. 258-63.	
L.M.A.		BERTSCHINGER, K. et al., Magnetic Resonance Myocardial First-Pass Perfusion Imaging: Parameter Optimization For Signal Response And Cardiac Coverage, Journal of Magnetic Resonance Imaging, 2001, vol. 14, pp. 556-62.	
<del></del>			
		•	
			-
		·	
·			
			<u></u>
Examiner	_	Date Date 11/04	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Considered

<sup>&</sup>lt;sup>1</sup>Unique cliation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.